Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
← catalyst calendarNCT07104565 · readout in 400 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
56estimated
Sites
40
Countries
Australia, France, Italy +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-29 | actual | When the study began enrolling |
| Primary completion | 2027-09-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-09 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Immune Thrombocytopenia
Intervention
- Drug: INCA000585
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to 52 weeks
Stable platelet response
measured After Day 56 up to Week 48
Stable hemoglobin response
measured After Day 56 up to Week 48
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed